PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Pharmacy, Centro Hospitalar de Lisboa Ocidental EPE, Lisbon, Portugal mffalcao@chlo.min-saude.pt.\', \'Social Pharmacy, Universidade de Lisboa Faculdade de Farmácia, Lisbon, Portugal.\', \'Pharmacy and Therapeutics Committee, Centro Hospitalar de Lisboa Ocidental EPE, Lisbon, Portugal.\', \'Pharmacy Department, Hospital de S. Francisco Xavier, Centro Hospitalar de Lisboa Ocidental EPE, Lisbon, Portugal.\', \'Pharmacy Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental EPE, Lisbon, Portugal.\', \'Polyvalent Intensive Care Unit, Hospital de S. Francisco Xavier, Centro Hospitalar de Lisboa Ocidental EPE, Lisbon, Portugal.\', \'Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.\', \'Surgical Intensive Care Unit. Hospital de S. Francisco Xavier, Centro Hospitalar de Lisboa Ocidental EPE, Lisbon, Portugal.\', \'Polyvalent Intensive Care Unit. Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental EPE, Lisbon, Portugal.\', \'Infecciology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental EPE, Lisbon, Portugal.\', \'Internal Medicine, Hospital de S. Francisco Xavier, Centro Hospitalar de Lisboa Ocidental EPE, Lisbon, Portugal.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1136/ejhpharm-2020-002613
?:doi
?:hasPublicationType
?:journal
  • European journal of hospital pharmacy : science and practice
is ?:pmid of
?:pmid
?:pmid
  • 33452110
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all